Oncology Pharma Inc
Oncology Pharma Inc., an oncology company, develops, manufactures, and commercializes therapeutics. The company has a collaboration and licensing agreement with Kalos Therapeutics Inc. for exploring treatment opportunities of the COVID-19 virus. The company was formerly known as SourcingLink.net Inc. and changed its name to Oncology Pharma Inc. in June 2019. Oncology Pharma Inc. was incorporated … Read more
Oncology Pharma Inc (ONPH) - Net Assets
Latest net assets as of December 2022: $1.10 Million USD
Based on the latest financial reports, Oncology Pharma Inc (ONPH) has net assets worth $1.10 Million USD as of December 2022.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($2.14 Million) and total liabilities ($1.04 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $1.10 Million |
| % of Total Assets | 51.44% |
| Annual Growth Rate | -1.42% |
| 5-Year Change | N/A |
| 10-Year Change | -66.2% |
| Growth Volatility | 36.15 |
Oncology Pharma Inc - Net Assets Trend (1996–2022)
This chart illustrates how Oncology Pharma Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Oncology Pharma Inc (1996–2022)
The table below shows the annual net assets of Oncology Pharma Inc from 1996 to 2022.
| Year | Net Assets | Change |
|---|---|---|
| 2022-03-31 | $1.25 Million | +833.54% |
| 2021-03-31 | $-170.01K | -167.04% |
| 2020-03-31 | $-63.66K | +70.06% |
| 2019-03-31 | $-212.62K | +3.47% |
| 2013-03-31 | $-220.27K | +45.52% |
| 2011-03-31 | $-404.27K | -135.04% |
| 2004-03-31 | $-172.00K | -119.72% |
| 2003-03-31 | $872.00K | -63.24% |
| 2002-03-31 | $2.37 Million | -35.71% |
| 2001-03-31 | $3.69 Million | -26.57% |
| 2000-03-31 | $5.02 Million | +9128.64% |
| 1998-03-31 | $-55.66K | -117.05% |
| 1997-03-31 | $326.38K | -81.97% |
| 1996-03-31 | $1.81 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Oncology Pharma Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 26495908000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (March 2022)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $188.89K | 15.15% |
| Other Comprehensive Income | $-188.89K | -15.15% |
| Other Components | $273.35 Million | 21918.67% |
| Total Equity | $1.25 Million | 100.00% |
Oncology Pharma Inc Competitors by Market Cap
The table below lists competitors of Oncology Pharma Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Candlewood Hotel Company Inc
PINK:CNDL
|
$0.93 |
|
Sphere Resources Inc
PINK:SPHUF
|
$0.93 |
|
APT Moto Vox Group Inc
PINK:MTVX
|
$0.93 |
|
Jupiter Marine International Holdings Inc
PINK:JMIH
|
$0.93 |
|
V Group Inc
PINK:VGID
|
$0.93 |
|
Davi Luxury Brand Group Inc
PINK:MDAV
|
$0.93 |
|
MPM Technologies Inc
PINK:MPML
|
$0.93 |
|
GuestLogix Inc
PINK:GUESF
|
$0.93 |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Oncology Pharma Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2021 to 2022, total equity changed from -170,012 to 1,247,093, a change of 1,417,105.
- Net loss of 104,626,728 reduced equity.
- Other comprehensive income decreased equity by 6,424.
- Other factors increased equity by 106,050,257.
Equity Change Factors (2021 to 2022)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-104.63 Million | -8389.65% |
| Other Comprehensive Income | $-6.42K | -0.52% |
| Other Changes | $106.05 Million | +8503.8% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Oncology Pharma Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.00x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2000-03-31 | $5024888.00 | $0.00 | x |
| 2001-03-31 | $3689734.00 | $0.00 | x |
| 2002-03-31 | $2372000.00 | $0.00 | x |
| 2003-03-31 | $872000.00 | $0.00 | x |
| 2004-03-31 | $-86000.00 | $0.00 | x |
| 2019-03-31 | $-0.18 | $0.00 | x |
| 2020-03-31 | $-0.04 | $0.00 | x |
| 2021-03-31 | $-0.01 | $0.00 | x |
| 2022-03-31 | $0.04 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Oncology Pharma Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -8389.65%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.70x
- Recent ROE (-8389.65%) is below the historical average (-698.58%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1996 | -149.78% | -262.79% | 0.33x | 1.73x | $-2.89 Million |
| 1997 | -851.08% | -217.93% | 0.74x | 5.26x | $-2.81 Million |
| 1998 | 0.00% | -281.42% | 0.93x | 0.00x | $-2.51 Million |
| 2000 | -89.92% | -454.82% | 0.15x | 1.33x | $-5.02 Million |
| 2001 | -43.19% | -39.72% | 0.78x | 1.39x | $-1.96 Million |
| 2002 | -82.25% | -53.13% | 1.02x | 1.52x | $-2.19 Million |
| 2003 | -174.31% | -46.34% | 1.87x | 2.01x | $-1.61 Million |
| 2004 | 0.00% | -132.51% | 24.60x | 0.00x | $-1.55 Million |
| 2011 | 0.00% | 43.60% | 0.51x | 0.00x | $99.25K |
| 2013 | 0.00% | 1821.37% | 0.05x | 0.00x | $208.16K |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-829.13K |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-201.19K |
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | $-97.46 Million |
| 2022 | -8389.65% | 0.00% | 0.00x | 1.70x | $-104.75 Million |
Industry Comparison
This section compares Oncology Pharma Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Oncology Pharma Inc (ONPH) | $1.10 Million | -149.78% | 0.94x | $0.93 |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |